<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> 

<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|frameless|upright=0.3|center]]
|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big>
|-
|}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
=All lines of therapy=
==Alemtuzumab monotherapy {{#subobject:9207db|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:45d126|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.jacionline.org/article/S0091-6749(09)00223-1/fulltext Wagner et al. 2009]
|style="background-color:#ffffbe"|Case report
|-
|}
====Chemotherapy====
*[[Alemtuzumab (Campath)]] 30 mg IV bi-weekly

'''Duration not specified'''

===References===
# '''Case report:''' Wagner LA, Speckart S, Cutter B, Gleich GJ. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J Allergy Clin Immunol. 2009 Jun;123(6):1407-8. Epub 2009 Apr 1. [http://www.jacionline.org/article/S0091-6749(09)00223-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19342084 PubMed]
# '''Retrospective:''' Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):287-91. Epub 2012 Nov 1. [http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(12)00202-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445419/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23123105 PubMed]

==Cladribine & Cytarabine {{#subobject:b80308|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d51fc2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.21186/full Jabbour et al. 2005]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|}
''Note that the timing of drug administration is in hours, starting at t = 0 hours.''
====Chemotherapy====
*[[Cladribine (Leustatin)]] 12 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started at 24 hours (total dose: 60 mg/m<sup>2</sup>)
*[[Cytarabine (Cytosar)]] 1000 mg/m<sup>2</sup> IV over 2 hours once per day at 0 hours, 48 hours, 72 hours, 96 hours, and 120 hours (5 doses total)

'''21-day cycle, repeated once if PR/CR; see text for definition of PR'''

===References===
# Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 1;104(3):541-6. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.21186/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15977212 PubMed]

==Hydroxyurea monotherapy {{#subobject:e819ce|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:4e5567|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annals.org/article.aspx?articleid=692211 Parrillo et al. 1978]
|style="background-color:#ffffbe"|Non-randomized, <20 pts
|-
|}
''To be completed; treatment details are not available in the abstract.''
====Chemotherapy====
*[[Hydroxyurea (Hydrea)]]

===References===
# Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978 Aug;89(2):167-72. [http://annals.org/article.aspx?articleid=692211 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/677578 PubMed]

==Imatinib monotherapy {{#subobject:77c7b0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:0be8cc|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08505-7/fulltext Gleich et al. 2002]
|style="background-color:#ffffbe"|Non-randomized, <20 pts
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa020150 Apperley et al. 2002]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|[http://www.bloodjournal.org/content/101/9/3391.long Pardanani et al. 2002]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|[http://www.bloodjournal.org/content/101/12/4714.long Cortes et al. 2003]
|style="background-color:#ffffbe"|Phase II, <20 pts
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa025217 Cools et al. 2003]
|style="background-color:#ffffbe"|Non-randomized, <20 pts
|-
|[http://www.bloodjournal.org/content/103/2/473.long Klion et al. 2003]
|style="background-color:#ffffbe"|Non-randomized, <20 pts
|-
|[http://www.haematologica.org/content/92/9/1173.long Baccarani et al. 2007]
|style="background-color:#91cf61"|Phase II
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07033.x/full Helbig et al. 2008]
|style="background-color:#ffffbe"|Non-randomized, <20 pts
|-
|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07294.x/full Metzgeroth et al. 2008]
|style="background-color:#91cf61"|Phase II
|-
|}
''Dosing is as described in the Metzgeroth et al. 2008 paper.''
====Chemotherapy====
*[[Imatinib (Gleevec)]] as follows:
**FIP1L1-PDGFRA positive patients: 100 mg PO once per day
**PDGFRB fusion positive or without known molecular aberration: 400 mg PO once per day

'''Continued for 12 months or longer at physician discretion'''

''Patients in Helbig et al. 2008 proceeded to a maintenance phase after 3 to 6 months of therapy which consisted of weekly dosing; dose not specified in the manuscript.''

===References===
# Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4;359(9317):1577-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08505-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12047970 PubMed]
# Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002 Aug 15;347(7):481-7. [https://www.nejm.org/doi/full/10.1056/NEJMoa020150 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12181402 PubMed]
## '''Pooled Update:''' Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014 Jun 5;123(23):3574-7. Epub 2014 Mar 31. [http://www.bloodjournal.org/content/123/23/3574.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047496/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24687085 PubMed]PubMed PMID: 24687085
# Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1;101(9):3391-7. Epub 2002 Dec 27. [http://www.bloodjournal.org/content/101/9/3391.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506022 PubMed]
# Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15;101(12):4714-6. Epub 2003 Feb 20. [http://www.bloodjournal.org/content/101/12/4714.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12595304 PubMed] 
# Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14. [https://www.nejm.org/doi/full/10.1056/NEJMoa025217 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12660384 PubMed]
# Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15;103(2):473-8. Epub 2003 Sep 22. [http://www.bloodjournal.org/content/103/2/473.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14504092 PubMed]
# Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1. [http://www.haematologica.org/content/92/9/1173.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17666373 PubMed]
# Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol. 2008 Apr;141(2):200-4. Epub 2008 Feb 26. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07033.x/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18307562 PubMed]
# Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008 Dec;143(5):707-15. Epub 2008 Oct 17. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07294.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18950453 PubMed]

==Mepolizumab monotherapy {{#subobject:39b7a4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:2ef22d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa070812 Rothenberg et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|Placebo
| style="background-color:#1a9850" |Superior primary endpoint
|-
|}
====Chemotherapy====
*[[Mepolizumab (Nucala)]] 750 mg IV once on day 1

'''21-day cycle for 8 cycles'''
===References===
# Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 Mar 20;358(12):1215-28. Epub 2008 Mar 16. Erratum in: N Engl J Med. 2008 Jun 5;358(23): 2530. [https://www.nejm.org/doi/full/10.1056/NEJMoa070812 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18344568 PubMed]
## '''Update:''' Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. Epub 2012 Oct 4. [http://www.jacionline.org/article/S0091-6749(12)01309-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23040887 PubMed]

==Nilotinib monotherapy {{#subobject:007581|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:267a4e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055104 Kantarjian et al. 2006 (A2101)]
|style="background-color:#ffffbe"|Phase I/II, <20 pts of this subtype
|-
|}
====Chemotherapy====
*[[Nilotinib (Tasigna)]] 400 mg PO twice per day

===References===
# '''A2101:''' Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [https://www.nejm.org/doi/full/10.1056/NEJMoa055104 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16775235 PubMed]
## '''Subgroup analysis:''' Hochhaus A, le Coutre PD, Kantarjian HM, Baccarani M, Erben P, Reiter A, McCulloch T, Fan X, Novick S, Giles FJ. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol. 2013 Dec;139(12):1985-93. Epub 2013 Sep 22. [http://link.springer.com/article/10.1007%2Fs00432-013-1529-7 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24057647 PubMed]

==Peginterferon alfa-2a monotherapy {{#subobject:010d91|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:72ed60|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.lrjournal.com/article/S0145-2126(11)00469-3/fulltext Butterfield et al. 2011]
|style="background-color:#ffffbe"|Case series
|-
|}

''The authors describe using peginterferon alfa-2b initially but switched to peginterferon alfa-2a when the first was "no longer available. Dosing details are not available in the abstract." 
====Immunotherapy====
*[[Peginterferon alfa-2a (Pegasys)]]

===References===
# '''Case series:''' Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res. 2012 Feb;36(2):192-7. Epub 2011 Nov 26. [http://www.lrjournal.com/article/S0145-2126(11)00469-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22118911 PubMed]

==Ruxolitinib monotherapy {{#subobject:87790c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:f86a11|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/31/17/e269.long Rumi et al. 2013]
|style="background-color:#ffffbe"|Case report
|-
|}
====Chemotherapy====
*[[Ruxolitinib (Jakafi)]] 15 mg PO twice per day

'''Duration not specified'''

===References===
# '''Case report:''' Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, Boni M, Bernasconi P, Passamonti F, Kralovics R, Cazzola M. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013 Jun 10;31(17):e269-71. Epub 2013 Apr 29. [http://jco.ascopubs.org/content/31/17/e269.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23630205 PubMed]

[[Category:Hypereosinophilic syndrome regimens]]
[[Category:Disease-specific pages]]
[[Category:Myeloproliferative neoplasms]]
